ru486

Drug Overview

Mifepristone (RU486) is a highly specialized medication utilized within the field of Endocrinology. It operates as a TARGETED THERAPY for patients suffering from severe metabolic complications associated with hypercortisolism. As a potent Glucocorticoid Receptor Antagonist, it blocks the physiological effects of excess cortisol rather than suppressing the body’s cortisol production.

• Generic Name: Mifepristone (historically RU486)
• US Brand Names: Korlym (for endocrinology indications)
• Drug Category: Endocrinology
• Drug Class: Glucocorticoid Receptor Antagonist
• Route of Administration: Oral tablet
• FDA Approval Status: FDA-Approved

What Is It and How Does It Work? (Mechanism of Action)

Mifepristone is a synthetic steroid compound that acts as a competitive antagonist at the glucocorticoid receptor. In conditions like Cushing’s syndrome, the body produces excessive amounts of cortisol, leading to severe metabolic derangements, including insulin resistance and hyperglycemia.

Instead of inhibiting the adrenal glands from synthesizing cortisol, mifepristone binds directly to the cellular glucocorticoid receptors with an affinity much higher than that of natural cortisol. By occupying these receptors, mifepristone blocks excess circulating cortisol from exerting its cellular effects. This competitive antagonism stops cortisol-induced gluconeogenesis in the liver and improves peripheral insulin sensitivity. Additionally, mifepristone exhibits potent antagonism at the progesterone receptor, which contributes to its other medical uses and specific side effect profile.

FDA-Approved Clinical Indications

• Primary Endocrinology Indication: * Cushing’s Syndrome Hyperglycemia: Mifepristone (under the brand name Korlym) is strictly indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is a TARGETED THERAPY to restore metabolic control.
• Other Approved & Off-Label Uses:
  • Medical Termination of Pregnancy (Approved): At a different dosage and brand name (Mifeprex), it is used as a progesterone receptor antagonist for the medical termination of intrauterine pregnancy.
  • Psychotic Major Depression (Off-Label): Investigated for rapid relief of psychotic depression due to its modulation of the hypothalamic-pituitary-adrenal (HPA) axis.
  • Meningioma (Off-Label): Used occasionally in cases of unresectable meningiomas that express progesterone receptors.

Dosage and Administration Protocols

Mifepristone requires strict administration protocols. It must be taken exactly as prescribed, consistently with a meal.

Dose Adjustments:

• Renal Impairment: The maximum dose is 600 mg daily for patients with severe renal impairment.
• Hepatic Impairment: The maximum dose is 600 mg daily for mild to moderate hepatic impairment. It is not recommended for severe hepatic impairment.
• CYP3A Inhibitors: Dose must be limited to 300 mg daily if co-administered with strong CYP3A inhibitors.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical efficacy is primarily measured by clinical and metabolic improvements rather than serum cortisol levels, which actually rise during therapy. Real-world data and long-term extensions of the SEISMIC trial (2020-2025) confirm mifepristone’s robust efficacy in controlling hypercortisolism-induced diabetes.

Research indicates that over 60% of Cushing’s patients treated with mifepristone achieve a clinically significant reduction in HbA1c, with mean reductions frequently exceeding 1.1%. Fasting plasma glucose levels drop rapidly upon initiation. Furthermore, because it blocks the lipogenic effects of cortisol, patients frequently experience a highly beneficial mean weight loss of 5% to 7% of their total body weight within the first six months of therapy, accompanied by significant reductions in waist circumference and improvements in global clinical status.

Safety Profile and Side Effects

BLACK BOX WARNING: PREGNANCY TERMINATION

Mifepristone has potent antiprogestational effects and will result in the termination of pregnancy. Pregnancy must be excluded before the initiation of treatment, or if treatment is interrupted for more than 14 days in females of reproductive potential. Nonhormonal contraceptives must be used during and for one month after stopping treatment.

Common side effects (>10%):

• Nausea and fatigue.
• Headache and dizziness.
• Hypokalemia (low potassium).
• Arthralgia (joint pain).
• Endometrial thickening and vaginal bleeding (due to progesterone antagonism).

Serious adverse events:

• Severe Hypokalemia: Because glucocorticoid receptors are blocked, excess circulating cortisol binds instead to unblocked mineralocorticoid receptors, driving severe potassium depletion and hypertension.
• Adrenal Crisis: Although circulating cortisol is high, the absolute blockade of receptors can precipitate a clinical state of adrenal insufficiency.

Management strategies:

• Routine potassium monitoring and aggressive oral potassium supplementation or administration of mineralocorticoid antagonists (like spironolactone) are frequently required.
• High-dose dexamethasone (which outcompetes mifepristone) must be readily available for emergency “sick day” protocols if acute adrenal insufficiency occurs.

Research Areas

Current research heavily focuses on mifepristone’s intense interaction with the HPA axis. Because it blocks cortisol at the receptor level, the pituitary gland senses a lack of cortisol and dramatically increases ACTH production, which in turn drives the adrenal glands to produce even more cortisol. This creates a highly complex biochemical environment. To mitigate the off-target effects caused by this massive cortisol surge (such as severe hypokalemia from mineralocorticoid receptor activation) and the progesterone-blocking side effects (endometrial thickening), clinical trials (2020-2026) have accelerated the development of highly selective, next-generation glucocorticoid receptor antagonists (e.g., relacorilant). These novel TARGETED THERAPY agents aim to provide the precise metabolic benefits of mifepristone—restoring insulin sensitivity and preventing macrovascular complications—without the mineralocorticoid or antiprogestational toxicity. 

Disclaimer: The research findings and developments regarding mifepristone and related next-generation glucocorticoid receptor antagonists are currently based on ongoing studies and investigational trials. These concepts remain exploratory and are not yet fully validated for routine clinical application or professional therapeutic use in standard medical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive metabolic panel (CMP), HbA1c, fasting lipids, and a highly sensitive serum pregnancy test for females of reproductive potential.
• Organ Function: Baseline renal function (eGFR) and hepatic monitoring (AST, ALT, bilirubin).
• Specialized Testing: Baseline serum potassium is critical; hypokalemia must be corrected before initiation.
• Screening: A baseline transvaginal pelvic ultrasound is strongly recommended for female patients to assess endometrial thickness.

Monitoring and Precautions

• Vigilance: Traditional hormone monitoring (measuring blood cortisol or ACTH) is useless for dose titration, as levels will be artificially elevated. Titration must be based strictly on clinical parameters: glycemic control, body weight, and signs of clinical adrenal insufficiency.
• Lifestyle: Medical Nutrition Therapy (MNT) focusing on low-sodium, high-potassium dietary intake is crucial to offset mineralocorticoid effects.
• Do’s and Don’ts:
  • DO use a highly reliable, non-hormonal barrier method of contraception during treatment and for one month after.
  • DO attend all scheduled blood draws to monitor potassium and glucose levels.
  • DON’T stop taking the medication abruptly without consulting your endocrinologist.
  • DON’T consume grapefruit or grapefruit juice, as it dramatically increases the medication’s toxicity by inhibiting its breakdown.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your endocrinologist, physician, or other qualified healthcare provider with any questions you may have regarding a medical condition, hormonal imbalance, or targeted therapy protocol. Never disregard professional medical advice or delay in seeking it because of something you have read here. Medication guidelines, FDA statuses, and clinical protocols are subject to change based on the latest medical research.